Table 1.
Shows a summary of the effect of emicizumab on the different coagulation assays
| Assay name | Sensitivity to emicizumab | Use in emicizumab-treated hemophilia A patients | |
|---|---|---|---|
| Coagulation Assays | aPTT | Oversensitive | Should not be used in emicizumab-treated patients |
| FVIII activity | FVIII one-stage assay | Oversensitive | Should not be used in emicizumab-treated patients |
| FVIII two-stage assay | Oversensitive | Should not be used in emicizumab-treated patients | |
| FVIII chromogenic substrate assay (human components) | Sensitive | For measurement of emicizumab effect | |
| FVIII chromogenic substrate assay (bovine components) | Insensitive | Can be used in emicizumab-treated patients to measure FVIII activity but not emicizumab activity | |
| Hemostasis monitoring | Clotting-based Bethesda assays | False-negative | Should not be used in emicizumab-treated patients |
| Chromogenic Bethesda assay (bovine components) | Insensitive | Can be used in emicizumab-treated patients to measure FVIII inhibitors |